Pharmaceutical The US Food and Drug Administration is coming under increasing pressure from other government authorities to review and provide clarity on off-label promotion regulations, as recent settlement agreements with pharmaceutical companies appear to give these companies license to extend previous working definitions of “scientific exchange” as allowed by law, notes Dr Nicola Davies in her monthly exclusive FDA Blog for The Pharma Letter. 22 June 2016